First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). | |
Hirsh, Vera; Yang, James Chih-Hsin; Tan, Eng-Huat; O'Byrne, Ken; Zhang, Li; Boyer, Michael J.; Mok, Tony; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai | |
2016 | |
卷号 | 34期号:15 |
ISSN号 | 0732-183X |
DOI | 10.1200/JCO.2016.34.15_suppl.9046 |
URL标识 | 查看原文 |
收录类别 | SCIE |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6384897 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Hirsh, Vera,Yang, James Chih-Hsin,Tan, Eng-Huat,et al. First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).[J],2016,34(15). |
APA | Hirsh, Vera.,Yang, James Chih-Hsin.,Tan, Eng-Huat.,O'Byrne, Ken.,Zhang, Li.,...&Park, Keunchil.(2016).First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs)..,34(15). |
MLA | Hirsh, Vera,et al."First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).".34.15(2016). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论